Growth Hormone Secretion in Pituitary Disease

Nelson, Jerald C.; Kollar, Denis; Lewis, J. E.

doi:10.1001/archinte.1974.00320150133018

Cited by 10 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T h e subnormal response of G H to /-dopa stimulation in the four patients with microadenomas verifies a number of previous reports that abnormalities in growth hormone are usually detectable at an earlier stage than are measurable deficiencies in other trophic hormone secretion (5).…”

Section: Discussionsupporting

confidence: 86%

“…The baseline values of Compound S and Cortisol, as well as the response to metyrapone, were normal in all six patients; the normal results of this test, as well as those of the T S H reserve test, verify the previous reports that T S H -and ACTH-secreting cells are the last to be affected and, therefore, are of little diagnostic value in detecting early pituitary tumors (5).…”

Section: Discussionsupporting

confidence: 81%

See 1 more Smart Citation

Evaluation and Treatment of Patients with Prolactin‐Secreting Pituitary Tumors

Fayez

Sowers

1980

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Six women with secondary amenorrhea and hyperprolactinemia, four of whom had associated galactorrhea, were studied. Four were found to have prolactin-secreting pituitary microadenomas and two had macroadenomas. Suppression of prolactin secretion and stimulation of prolactin, serum growth hormone and thyroid-stimulating hormone secretion were studied, and gonadotropin and adrenocorticotropic hormone reserves were evaluated. The most sensitive techniques available for the diagnosis of pituitary adenomas in patients with amenorrhea and hyperprolactinemia appear to be the measurement of the magnitude of plasma prolactin elevation and hypocycloidal tomography of the sella turcica. The dynamic function tests proved to be of little diagnostic, but of great prognostic, value for patients with small pituitary tumors.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionsupporting

confidence: 81%

Evaluation and Treatment of Patients with Prolactin‐Secreting Pituitary Tumors

Fayez

Sowers

1980

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

Abnormal sella turcica. A tumor board review of the clinical significance

Kurnick¹

1977

Archives of Internal Medicine

View full text Add to dashboard Cite

Restenosis following coronary angioplasty

Karas

Santoian

Gravanis

1991

Clinical Cardiology

View full text Add to dashboard Cite

Summary:Restenosis is the most important problem limiting the success of coronary angioplasty. Clinically, restenosis is seen in approximately one-third of patients undergoing percutaneous transluminal coronary angioplasty. Several clinical and angiographic risk factors have been identified which may contribute to the development of restenosis. Histopathologic studies indicate that restenosis is characterized by intimal proliferation of smooth muscle cells in a loose connective tissue matrix. These intimal lesions are associated predominantly with the nonatheromatous portion of the vessel wall. Thinning of the media of the plaque-free wall and marked fragmentation of the internal elustic lamina are also seen. Traumatic injury of the vessel wall during angioplasty probably triggers a series of cellular und subcellular events which may ultimately lead to niyointimal proliferation and restenosis. Although the exact mechanism by which this occurs is unknown, several factors may enhance smooth muscle cell growth and therefore may play a role in the development of restenosis. These include platelet deposition, mechanical stretching of the medi,a, inflammation of the vessel wall, the activity of growth factors, and alterations in vessel geometry. These possible mechanisms of restenosis suggest several potential ways to limit the proliferative response to vascular injury.Anticoagulants and platelet antagonists, direct inhibitors of smooth inuscle proliferation, anti-inflammatory agents, growth factor inhibitors, and new devices which improve final vessel geometry are currently being tested as methods to curb restenosis. Unfortunately, no treatment has yet been shown to reduce significantly the rate of restenosis following angioplasty. The problem of restenosis will most likely be solved by better understanding of the basic molecular and biologic phenomena involved in vascular injury and repair.

show abstract

Growth Hormone Secretion in Pituitary Disease

Cited by 10 publications

References 37 publications

Evaluation and Treatment of Patients with Prolactin‐Secreting Pituitary Tumors

Evaluation and Treatment of Patients with Prolactin‐Secreting Pituitary Tumors

Abnormal sella turcica. A tumor board review of the clinical significance

Restenosis following coronary angioplasty

Contact Info

Product

Resources

About